Cargando…

Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations

Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajore, Ram, Raiser, David, McConkey, Marie, Jöud, Magnus, Boidol, Bernd, Mar, Brenton, Saksena, Gordon, Weinstock, David M, Armstrong, Scott, Ellis, Steven R, Ebert, Benjamin L, Nilsson, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376749/
https://www.ncbi.nlm.nih.gov/pubmed/28264936
http://dx.doi.org/10.15252/emmm.201606660
_version_ 1782519212200165376
author Ajore, Ram
Raiser, David
McConkey, Marie
Jöud, Magnus
Boidol, Bernd
Mar, Brenton
Saksena, Gordon
Weinstock, David M
Armstrong, Scott
Ellis, Steven R
Ebert, Benjamin L
Nilsson, Björn
author_facet Ajore, Ram
Raiser, David
McConkey, Marie
Jöud, Magnus
Boidol, Bernd
Mar, Brenton
Saksena, Gordon
Weinstock, David M
Armstrong, Scott
Ellis, Steven R
Ebert, Benjamin L
Nilsson, Björn
author_sort Ajore, Ram
collection PubMed
description Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53‐intact tumors (P ≪ 10(−10)), and shRNA‐mediated knockdown of RPGs activated p53 in TP53‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically.
format Online
Article
Text
id pubmed-5376749
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53767492017-04-05 Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations Ajore, Ram Raiser, David McConkey, Marie Jöud, Magnus Boidol, Bernd Mar, Brenton Saksena, Gordon Weinstock, David M Armstrong, Scott Ellis, Steven R Ebert, Benjamin L Nilsson, Björn EMBO Mol Med Research Articles Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53‐intact tumors (P ≪ 10(−10)), and shRNA‐mediated knockdown of RPGs activated p53 in TP53‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically. John Wiley and Sons Inc. 2017-03-06 2017-04 /pmc/articles/PMC5376749/ /pubmed/28264936 http://dx.doi.org/10.15252/emmm.201606660 Text en © 2017 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Ajore, Ram
Raiser, David
McConkey, Marie
Jöud, Magnus
Boidol, Bernd
Mar, Brenton
Saksena, Gordon
Weinstock, David M
Armstrong, Scott
Ellis, Steven R
Ebert, Benjamin L
Nilsson, Björn
Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
title Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
title_full Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
title_fullStr Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
title_full_unstemmed Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
title_short Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
title_sort deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with tp53 mutations
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376749/
https://www.ncbi.nlm.nih.gov/pubmed/28264936
http://dx.doi.org/10.15252/emmm.201606660
work_keys_str_mv AT ajoreram deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT raiserdavid deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT mcconkeymarie deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT joudmagnus deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT boidolbernd deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT marbrenton deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT saksenagordon deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT weinstockdavidm deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT armstrongscott deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT ellisstevenr deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT ebertbenjaminl deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations
AT nilssonbjorn deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations